Screened 2026-09-08 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
UCB SA holds its Markdown at $120.27. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-09-08
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$120.27
Valuation
18.33 trailing · 15.23 forward price to earnings
Values screen
PASS
Beta
0.18
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.20%
Below 33%
Interest-bearing debt is just 4.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.42%
Below 33%
Cash held in interest-bearing accounts and securities is 4.4% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 37.2% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus Strong Buy. The average target sits +36% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Drugmaker Growth Trading Below Its Potential
Think of a patient in Europe finally accessing a new treatment for severe epilepsy or psoriasis. The royalties and sales that follow depend on one mid-sized company steadily expanding its pipeline. UCB delivers revenue growth of 27 percent alongside 20 percent profit margins and 15 percent return on equity, all at a forward multiple of 17.7 times with our fair value sitting 21 percent higher.
The moderate moat and strong buy consensus from two analysts support the case for a business that converts innovation into cash without needing heroic assumptions. A 21 percent margin of safety provides breathing room if execution stays on track.
Risks remain real though. Patent expiries and rival pipelines can erode pricing power faster than expected in this sector, while a moderate moat offers limited protection against setbacks in late-stage trials. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UCBJY trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.7% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (2 analysts) rates it strong buy, with a mean price target of $163.
2026-07-18Markup$149.54+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (2 analysts) rates it strong buy, with a mean price target of $163.
2026-07-03Markup$149.54+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$149.54Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.